Drugs / Nanocovax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04683484 | Dec 2020 → Jun 2021 | COVID-19 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04922788 | Jun 2021 → Jul 2022 | COVID-19 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2020-12-10 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Regulatory Calling for volunteers of Nanogen's Covid-19 vaccine clinical trial nanogenpharma.com ↗
NANO COVAX accomplished pre-clinical trials and was approved by authorities to conduct a clinical trial from December 10th, 2020. |
| 2020-12-09 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Regulatory Vietnam eyes launch of homemade COVID vaccine in 2nd half of 2021 (Nikkei Asia) nanogenpharma.com ↗
Vietnamese authorities have told Nanogen Pharmaceutical Biotechnology to proceed with clinical trials of a COVID-19 vaccine, giving a shot in the arm to the Ho Chi Minh City-based company's efforts to roll out a "made in Vietnam" vaccine next year. |
| 2020-12-09 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Results RESULTS OF CLINICAL TESTING OF PHASE 1 & PHASE 2 OF NANOCOVAX VACCINE nanogenpharma.com ↗
The phase of determining the vaccine achieved high safety, no serious adverse events occurred, mainly adverse events were mild (grade 1) and resolved quickly after injection. |
| 2020-12-09 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Regulatory REGISTER TO PARTICIPATE IN THE NANOCOVAX PHASE 3 CLINICAL TRIAL nanogenpharma.com ↗
Based on the very good results of phase 1 and phase 2, at noon on June 11, 2021, the Ministry of Health officially approved the phase 3 trial protocol of Nanocovax vaccine (25 mcg/mL) of Nanogen company. |
| 2020-12-09 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Results PRECLINICAL TRIAL RESULTS OF NANOCOVAX VACCINE nanogenpharma.com ↗
The test results show that, after injecting the Nanocovax sample: Mice did not have abnormal expressions, ate, worked normally, and all gained weight during the test. |
| 2020-12-09 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Results CLINICAL TRIAL PHASE 3: HIGH PROTECTION IS POSSIBLE WITH NANOCOVAX nanogenpharma.com ↗
As a result, the vaccine is safe, 100% of the volunteers are immune, the seroconversion rate reaches 99.4% and the antibodies produced can fight against the Wuhan virus and new strains. |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanocovax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04922788 ↗ |
| Modality | Vaccine | “a SARS-CoV-2 recombinant spike protein vaccine” PMID 35602004 ↗ May 2022 |
| Route | Intramuscular | “two intramuscular injection of the vaccine” PMID 35602004 ↗ May 2022 |